Schedule III Could Spawn Pharma-Adjacent Cannabis Startups

Photo by Beelith USA via Pexels.

Rescheduling marijuana to Schedule III would do two big things: it would likely end the Section 280E tax penalty for state-licensed operators, and it would loosen the federal grip on research. It would not make a state-licensed adult-use sale legal under federal law. Headlines often blur that line, and some business plans rest on the blur.

One caution first. The rulemaking status has been moving, and I could not verify it while writing this. Everything about the proposed rule, the stalled hearing and any executive action below is background from memory. Check the Federal Register and docket DEA-1362 before you act on any of it.

Here is the frame. If Schedule III arrives in something like its proposed form, the interesting money may flow to companies that look more like specialty pharma suppliers than dispensaries. Below are three places such startups could form, the precedents that suggest how it might go, and the ways it could fail.

What Schedule III Changes, and What It Leaves Alone

Start with what is background to verify. HHS recommended Schedule III in 2024, and DOJ and DEA followed with a proposed rule. The administrative hearing was then stalled amid litigation and leadership changes. I can't tell you where it stands now, so confirm on federalregister.gov and in docket DEA-1362 before stating a status.

Now the settled-law layer. Section 280E of the tax code denies ordinary business deductions to traffickers in Schedule I and II substances. Move marijuana to Schedule III and 280E would likely stop applying to state-licensed operators. That is a reading of the statute, though, and the final rule text and any carve-outs decide how it plays out.

Schedule III is also not a free-for-all. Manufacturers and distributors of a Schedule III substance still need DEA registration. A drug marketed as a medicine still needs FDA approval, and anything sold outside that pathway stays subject to controlled-substance rules.

From there, the reasoned extrapolation. State-licensed adult-use shops would probably remain in a federal gray zone, because rescheduling does not create a federal pathway for recreational retail. So the new startup openings are unlikely to be in retail. Retail operators get a tax break; the formation of new companies happens upstream, where federal rules reward rigor.

Here is a quick sorting of what is firm and what is not:

• Settled law: 280E covers Schedule I and II; DEA registration and FDA approval requirements apply to Schedule III drugs.
• Depends on the final rule: exact scope, carve-outs, effective date, and how state-licensed activity is treated.
• Open speculation: how fast DEA processes new registrations and how many applicants it can handle.

The Precedents: Marinol, Epidiolex and the Hemp Boom

History offers a few templates. Dronabinol, sold as Marinol, was moved from Schedule II to Schedule III around 1999 (verify the date). It shows that a cannabinoid drug can sit comfortably in Schedule III once FDA has approved it. The schedule followed the approval, not the other way round.

Epidiolex is the stronger precedent. In 2018 it became the first FDA-approved plant-derived cannabis drug, and DEA later removed it from the schedules after its approval (verify both dates). The lesson is that a plant-derived product with a clean data package can get through. GW Pharmaceuticals won by doing the trials, not by lobbying around them.

The cautionary case is hemp. The 2018 Farm Bill set off a rush of CBD startups, but FDA never built a clear route for CBD as a supplement. The result was a gray market with uneven quality and uncertain legal footing. Companies that bet on regulatory clarity arriving by itself were left waiting.

If I extrapolate from the three, the winners were firms that treated regulation as a product feature. They built quality systems, data and documentation before the market demanded them. That is a pattern, not a law, but it's the one I'd bet on again.

The counter-case deserves equal weight. Both drug precedents took years, and neither started with rescheduling alone. Rescheduling creates no approved product. It lowers some barriers, and a startup still has to carry a molecule or formulation through trials, which is slow and expensive. Anyone promising a near-term payoff from the Epidiolex path is skipping that arithmetic.

Opening One: Research Infrastructure and Clinical Trial Services

Photo by Mikhail Nilov via Pexels.

Schedule I status makes cannabis research cumbersome. Researchers have faced heavy registration and protocol requirements and limited material. Schedule III would likely ease these, though DEA registration would still be needed, and the final rule will say how much. Don't assume the friction vanishes.

That friction is the opening. One concept is a contract research organization specializing in cannabinoid trials. It would handle dosing protocols, patient recruitment and chemovar standardization, the unglamorous parts that sponsors struggle with when they have no cannabis experience. A pharma company curious about cannabinoids might prefer renting that expertise to building it.

A second concept is a real-world evidence platform. State medical programs hold large volumes of patient-reported data on what people use and how they feel. Turning that into datasets FDA could use is plausible in principle. The data-quality problem is severe, though: products vary by batch, dosing is self-directed, and outcomes are self-reported. A platform that can't solve that is just a database.

The more speculative idea is academic spinouts licensing standardized cannabis material for trials. Universities could become suppliers of well-characterized research material. I have no sourced count of such ventures, so treat this as an open possibility rather than a trend.

The counter-case is plain. Clinical trials cost a lot, the evidence base for many proposed indications is thin, and early-stage funding may stay scarce even after rescheduling. Investors who got burned in the hemp cycle will want milestones before they write checks. A research-services startup that depends on a few trial sponsors is exposed if those sponsors hesitate.

Opening Two: GMP Manufacturing, Formulation and Delivery

An FDA-approved product needs pharmaceutical-grade manufacturing, meaning cGMP. Most state-licensed cultivators and extractors do not currently meet that standard. They are built for state compliance and consumer products, not for the batch records, validated processes and quality systems that drug manufacturing demands. That gap is a business.

One concept is a GMP-grade cannabinoid API supplier, or a contract manufacturer serving drug developers. Developers who want to run trials need consistent, documented material, and few have a source. A small firm that builds the facility and quality systems once could serve many sponsors.

Another is formulation and delivery work. Think inhalers, sublingual films and consistent-dose oral forms. Cannabinoids are notoriously variable in how much reaches the bloodstream, so bioavailability is the scientific hurdle. That is where defensible intellectual property tends to live, more than in the plant itself.

A plant-derived product would likely follow FDA's botanical drug development guidance. I'd verify the current version before citing specifics, since guidance gets revised. The point is that a pathway for botanicals exists, and Epidiolex walked it.

Now the counter-case. DEA registration and production quotas could throttle supply, and quota decisions sit outside any startup's control. Big pharma could also buy or out-build small players once the path looks safe. A founder should assume that a good formulation may end up as an acquisition target, not an independent company, and plan for that outcome rather than resent it.

Opening Three: Compliance, Tax and Dual-Regime Software

Projection first: if 280E ends, operators will restructure their books, and accountants and software vendors will compete to manage the transition. I'm stating this as expectation, not fact. The timing depends on the final rule's effective date and on how the IRS treats prior periods.

One software concept is a compliance tool that tracks both state seed-to-sale rules and federal controlled-substance recordkeeping. Today these are separate worlds. A firm that reconciles them could be useful to any operator that registers with DEA, and to any pharma partner auditing a supplier.

Another is the analytical lab offering pharmacopeial-style testing. Quality standards matter more once pharma buyers arrive, because their auditors ask harder questions than a state regulator does. Labs that invest in validated methods early could become the default. This is also one of the few ideas here that earns revenue even if drug development stalls.

An assumption I'll state openly: tax savings get reinvested in R&D or growth. The counter-case is just as likely. Many operators carry heavy debt and thin margins, and much of the freed cash may go to paying down loans and shoring up profit. If so, demand for new services will be slower than the optimistic story implies.

Banking is the other variable. SAFER Banking and the STATES 2.0 Act are the bills usually named, but I haven't confirmed their status on congress.gov. Check that before building anything that depends on either passing.

What Could Stall It, and How a Founder Should Hedge

Photo by Kindel Media via Pexels.

The risks are concrete. The rule could be delayed or reversed by litigation, as the earlier hearing was stalled. I can't confirm the current docket status, so a founder should read it directly rather than rely on commentary, including this article.

A second risk is the gap between rescheduling and any approved product. Revenue from a drug could be years away, and the timeline is not established. Third, established pharma and multistate operators hold capital and regulatory teams that startups lack, and they can move faster once the path is clear.

The hedge is to pick business lines that earn revenue under any outcome. Testing, software and contract services all qualify, since they serve whoever ends up in the market. Build those, then stay option-ready for drug development through partnerships, licensed IP or a staged plan that adds clinical work when funding allows.

Four signposts are worth watching over the next one to three years:

1. Publication of a final rule, and what its text says about scope and carve-outs.
2. How quickly DEA processes registrations for manufacturers, distributors and researchers.
3. The first new INDs for cannabis-derived candidates.
4. Any FDA statements on botanical products or cannabinoid pathways.

If none of these move, the thesis is early, and a founder who hedged will still be operating.

The most useful read of Schedule III is that it lowers the cost of being a serious cannabis science business more than it widens the market for selling cannabis. Retail stays in its gray zone. The cheaper thing is rigor: registered labs, qualified manufacturing, trial-ready data.

So treat the rule text and the docket as the source of truth, and read them before any commentary. Every startup idea above is a bet with named assumptions, such as final rule scope, DEA throughput, reinvested tax savings and available funding. If one of those assumptions breaks, change the plan.

Browse our seed collection.